Uppsala är en tätort i Uppland, centralort i Uppsala kommun och residensstad för Uppsala län. Den är Sveriges fjärde största tätort med 165 456 invånare i tätorten, medan hela kommunen har cirka 238 000 invånare. Sedan 1164 är Uppsala kyrkligt centrum i Sverige i och med dess ärkebiskopssäte inom Svenska kyrkan.

During the past decade, SE-Uppsala-UPPSALAUH conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "SE-Uppsala-UPPSALAUH" #1 collaborator was "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator, "Central European Myeloma Study Group" with 1 trials as a collaborator, "DSMM (Deutsche Studiengruppe Multiples Myelom)" with 1 trials as a collaborator and "European Myeloma Network" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "SE-Uppsala-UPPSALAUH" are "Acute Myeloid Leukemia" (2 trials), "Myelodysplastic Syndrome With Excess Blasts-2" (2 trials), "Chronic Lymphocytic Leukemia in Relapse" (1 trials), "Chronic Lymphocytic Leukemia in Remission" (1 trials) and "Multiple Myeloma" (1 trials). Many other conditions were trialed in "SE-Uppsala-UPPSALAUH" in a lesser frequency.

Most popular intervention types in "SE-Uppsala-UPPSALAUH" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "1 or 2 cycle(s) HDM (High Dose Melphalan)" (1 trials), "2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)" (1 trials), "AG-120" (1 trials), "AG-221" (1 trials) and "Bortezomib, Melphalan, Prednisone (VMP)" (1 trials). Other intervention names were less common.

The vast majority of trials in "SE-Uppsala-UPPSALAUH" are 4 trials for "All" genders.

Currently, there are NaN active trials in "SE-Uppsala-UPPSALAUH". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in SE-Uppsala-UPPSALAUH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in SE-Uppsala-UPPSALAUH, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".